TG Therapeutics (TGTX) Tops Q2 EPS by 21c

TG Therapeutics (NASDAQ: TGTX) reported Q2 EPS of ($0.30), $0.21 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $594 thousand versus the consensus estimate of $175.43 thousand.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform